CRLF2

CRLF2

A gene on chromosome Xp22.3 and Yp11.3 that encodes a protein receptor for thymic stromal lymphopoietin (TSLP), which forms a functional complex with TSLP and IL7R and stimulates cell proliferation by activating STAT3 and STAT5, as well as JAK2. It is
implicated in the development of the haematopoietic system.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
Leukemias with these genetic profiles frequently demonstrate translocations of other tyrosine kinases, or alternatively have translocations involving the CRLF2 gene.
In addition, a CRLF2 rearrangement was observed in 51% of cells analyzed, and an extra IgH signal was present in 57% of cells, likely due to a translocation with CRLF2.
(15,16) The recent description of BCR-ABLl-like ALL (2,3) will probably result in an increase in future testing for other abnormalities associated with this poor-prognosis ALL type, such as CRLF2 translocations, which were uncommonly tested for in this survey.
This approach identified the "IL-7R network" which is comprised of the following proteins: IL2RG, IL-7, TSLP, CRLF2, JAK1, and JAK3.
We have presented the most significantly deregulated genes between cPTC and fvPTC: TMPRSS11, CEACAM6, ACTBL2, FN1, CRLF2, LDLR, LY6G6C, and TM7SF4 (Figure 2).
In Down syndrome, aberrant expression of CRLF2 is associated with mutated JAK2, suggesting that blocking the CRLF2/JAK2 pathway may be an effective method for Down syndrome therapy (8).
In addition, rs1054564 was associated with trans expression of the CRLF2 (cytokine receptor-like factor 2) gene, located on chromosome Xp22.3 (P = 1.61 X [10.sup.-11], and the LRRC31 (leucine rich repeat containing 31) gene, which is on chromosome 3q26.2 (P = 2.87 X [10.sup.-11]).
(51,52) CRLF2 translocations have more recently been found in 7% to 14% of de novo B-ALL and 53% of Down syndrome-associated B-ALL.
In some ALL patients, chromosomal translocations create ABL1/NUP214 or P2RY8/ CRLF2 fusion proteins with oncogenic activity (41), (42).
Mutations in CRLF2, IKZL1, TP53, ERG, and NOTCH have also been detected in precursor B and T lymphoblastic leukemia/lymphoblastic lymphoma and confer an adverse prognosis.